Carriers of DMD and BMD
are at higher than average risk of developing cardiomyopathy. The academy suggests that carriers should undergo a complete cardiac evaluation in late adolescence or early adulthood, or sooner if symptoms occur, and that they should be evaluated every five years starting at age 25 to 30.
There’s some evidence that treatment with angiotensin converting enzyme (ACE) inhibitors and beta blockers can slow the course of cardiac muscle deterioration in DMD and BMD.
This is effective if the medications are started as soon as abnormalities on an echocardiogram (ultrasound imaging of the heart) appear but before symptoms occur.
Some people with BMD who have severe heart problems but generally good health have been successfully treated with heart transplants
Manifesting Carrier of Duchenne Muscular Dystrophin
A mutation in the gene for the muscle protein dystrophin. The classic definition of a disease carrier is someone who can pass the disease to others but doesn't show symptoms. But manifesting carriers are carriers who show {manifest} symptoms of the disease themselves. Some estimates are that as-many as one in ten carriers of DMD or its less severe variant,BMD have signs of the disease themselves. Usually, the signs are relatively mild-but not always.
There’s some evidence that treatment with angiotensin converting enzyme (ACE) inhibitors and beta blockers can slow the course of cardiac muscle deterioration in DMD and BMD.
This is effective if the medications are started as soon as abnormalities on an echocardiogram (ultrasound imaging of the heart) appear but before symptoms occur.
Some people with BMD who have severe heart problems but generally good health have been successfully treated with heart transplants